Samsung Biologics announced on Feb. 13 that it has been awarded the Leadership A- grade in the climate change response category by global sustainability evaluation organization Carbon Disclosure Project (CDP). CDP, a non-profit international organization founded in the U.K. in 2000, conducts projects requesting disclosure of information related to environmental issue responses from major listed companies worldwide. In 2023, approximately 23,000 companies participated.
The CDP evaluation is used by global pharmaceutical companies such as GSK, AstraZeneca, Novartis, and investors as an indicator to understand a company’s level of response to climate change. It is recognized as a credible sustainability indicator along with the Dow Jones Sustainability Index (DJSI) and others. Top grades are awarded to companies that receive an overall excellent evaluation in their climate change response strategies, objectives, and implementation.
Samsung Biologics, in 2021, became the first in the domestic pharmaceutical and biotech industry to participate in CDP and received the second highest Management grade in its first year of evaluation. Maintaining the same grade in 2022, the company was upgraded to Leadership A- grade in the 2023 evaluation. This places Samsung Biologics at the same level as AstraZeneca, GSK, Johnson & Johnson, and Sanofi, acknowledging its outstanding capability in responding to climate change alongside global big pharma companies.
Aiming for a 2050 Net Zero goal, Samsung Biologics has been recognized for its efforts in reducing greenhouse gas emissions through energy saving and renewable energy conversion at its sites, participating in global initiatives such as RE100, the Sustainable Markets Initiative (SMI), and the United Nations Global Compact (UNGC), and continuously enhancing its support and management for carbon-neutral supply chains.
The company has been continuously engaged in activities to reduce greenhouse gas emissions, including the installation of solar power generation facilities, replacing boilers with high-efficiency ones and setting up a Factory Energy Management System (FEMS). It is also advancing its supply chain response policies by conducting ESG agreements with suppliers, establishing a sustainable product purchasing policy, enhancing supply chain ESG evaluations, and planning to further expand support activities for its partners.
John Rim, CEO of Samsung Biologics, stated, “We will continue to innovate, such as expanding the transition to renewable energy, to strengthen our leadership in climate change. We will continue our efforts in sustainable management to be trusted by various stakeholders and contribute to a better future for humanity.”